How to manage IBD in patients with infections or malignancies?

Digestive Diseases

Volumn 30, Issue 4, 2012, Pages 420-424

  Kohn, Anna ^a,b   Meddi, Patrizia ^a  

^a AO San Camillo Forlanini   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

IBD management; Infections; Malignancies

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IPILIMUMAB; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; VINCRISTINE;

ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; CANDIDIASIS; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; COMORBIDITY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG SAFETY; ENTERITIS; ENTEROCOLITIS; ENTEROPATHY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFECTION RISK; INTESTINE BIOPSY; KIDNEY CARCINOMA; MELANOMA; MYCOBACTERIOSIS; MYCOSIS; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; SIGMOIDOSCOPY; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; VIRUS INFECTION; VIRUS REACTIVATION;

HUMANS; INFECTION; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; RISK FACTORS;

EID: 84863891504     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000338145     Document Type: Article

References (32)

1. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, Doménech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SP, Colombel JF; on behalf of the European Crohn's and Colitis Organisation (ECCO): European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
2. Toruner M, Loftus EV Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936.
3. Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A: Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 30-35.
4. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM: Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365.
5. del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R: Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701-702.
6. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
7. Campbell S, Gosh S: Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13: 191-192.
8. Magliocco MA, Gottlieb AB: Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580-584.
9. Beltrán B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J: Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 2006; 55: 1670-1671.
10. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD: The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67: 710-712.
11. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
12. Aberra FN, Stettler N, Bresinger C, et al: Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 2007; 5: 1070-1075.
13. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206.
14. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49: 1-51.
15. British Thoracic Society Standards of Care Committee: Recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-treatment. Thorax 2005; 60: 800-805.
16. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351.
17. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW, European Crohn's and Colitis Organization (ECCO): Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection . Clin Gastroenterol Hepatol 2009; 7: 981-987.
18. Goodman MJ, Truelove SC: Intensive intravenous regimen for membranous colitis. Br Med J 1976; 2: 354.
19. Vega R, Bertran X, Menacho M, et al: Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1053-1056.
20. Cottone M, Pietrosi G, Martorana G, et al: Prevalence of Cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001; 96: 773-775.
21. Lortholary O, Perronne C, Leport J, et al: Primary Cytomegalovirus infection associated with the onset of ulcerative colitis. Eur J Clin Microbiol Infect Dis 1993; 12: 570-572.
22. Loftus EV Jr., Alexander GL, Carpenter HA: Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol 1994; 19: 306-309.
23. Shimada Y, Iiai T, Okamoto H, et al: Toxic megacolon associated with Cytomegalovirus infection in ulcerative colitis. J Gastroenterol 2003; 38: 1107-1108.
24. Davignon JL, Boyer JF, Jamard B, Nigon D, Constantin A, Cantagrel A: Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments. Arthritis Res Ther 2010; 12:R142.
25. Kandiel A, Lashner B: Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2857-2865.
26. Wöhrer S, Troch M, Zwerina J, Schett G, Skrabs C, Gaiger A, Jaeger U, Zielinski CC, Raderer M: Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol 2007; 18: 647-651.
27. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289.
28. Brem R, Li F, Montaner B, Reelfs O, Karran P: DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation. Oncogene 2010; 29: 3953-3963.
29. Raaschou P, Simard JF, Neovius M, Askling J, Anti-Rheumatic Therapy in Sweden Study Group: Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011; 63: 1812-1822.
30. Katoulis AC, Kanelleas A, Zambacos G, Panayiotides I, Stavrianeas NG: Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology 2010; 221: 9-12.
31. Szlosarek PW et al: Expression and regulation of tumour necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 2006; 5: 382-390.
32. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F: The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585-592.